Disease area hub

Ophthalmology clinical trial failures

Review 260 stopped ophthalmology clinical trials, including failure signals, sponsors, phases, and stop reasons from ClinicalTrials.gov records.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 34 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials260
Likely biological signals34
Shown below100

Dominant stop reasons

OTHER/UNKNOWN
120
OPERATIONAL
106
EFFICACY/FUTILITY
22
SAFETY
12

Notable sponsors

Asociación para Evitar la Ceguera en México
14
Novartis Pharmaceuticals
8
Allergan
6
Johns Hopkins University
6
Laboratorios Sophia S.A de C.V.
5

Related phases

Phase II
79
Phase IV
63
Phase III
49
Phase I
46
Unknown
20

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05126966: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Phase III Neovascular Age-Related Macular Degeneration trial by Hoffmann-La Roche. Stop reason: EFFICACY/FUTILITY.

Roche/Genentech has initiated an immediate pause of all new PDS implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use